J. M. Neuner

Anthracycline-containing versus anthracycline-free carboplatin-based regimens in early-stage triple-negative breast cancer: real-world outcomes

Triple‑negative breast cancer (TNBC) is an aggressive disease with poor survival outcomes. With the integration of immunotherapy, the optimal neoadjuvant chemotherapy backbone remains poorly defined. We examined real-world treatment patterns and response rates among patients receiving a carboplatin-based regimen, with...